Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy

NCT00597909 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated due to lack of enrollment and business decisions.

Conditions

Hepatic Encephalopathy

Interventions

DRUG: sodium phenylacetate and sodium benzoate injection 10% / 10%
DRUG: sodium phenylacetate and sodium benzoate injection 10% / 10%
DRUG: placebo solution (10% dextrose)

Sponsor

Amgen